Allan J. Barnes

ORCID: 0000-0001-7780-3504
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Forensic Toxicology and Drug Analysis
  • Cannabis and Cannabinoid Research
  • Neurotransmitter Receptor Influence on Behavior
  • Alcohol Consumption and Health Effects
  • Psychedelics and Drug Studies
  • Prenatal Substance Exposure Effects
  • Neuroscience of respiration and sleep
  • Analytical Chemistry and Chromatography
  • Metabolomics and Mass Spectrometry Studies
  • Mass Spectrometry Techniques and Applications
  • Analytical Methods in Pharmaceuticals
  • Poisoning and overdose treatments
  • Hormonal and reproductive studies
  • Sleep and Wakefulness Research
  • Opioid Use Disorder Treatment
  • Cerebrospinal fluid and hydrocephalus
  • Advanced Chemical Sensor Technologies
  • Neuroscience and Neuropharmacology Research
  • Microfluidic and Capillary Electrophoresis Applications
  • Ziziphus Jujuba Studies and Applications
  • Analytical Chemistry and Sensors
  • Child and Adolescent Psychosocial and Emotional Development
  • Coffee research and impacts
  • Chemical synthesis and alkaloids
  • Maternal Mental Health During Pregnancy and Postpartum

Johns Hopkins Medicine
2010-2024

Johns Hopkins University
2010-2024

National Institute on Drug Abuse
2011-2020

National Institutes of Health
2009-2020

Quest Diagnostics (United States)
2018-2020

United States Drug Testing Laboratories
2018

British Lung Foundation
2016

Food and Drug Administration
2008

Maryland Medical Research Institute
1993

There is increasing interest in markers of recent cannabis use because following frequent intake, Δ9-tetrahydrocannabinol (THC) may be detected blood for up to 30 days. The minor cannabinoids cannabidiol, cannabinol (CBN), and THC-glucuronide were previously ≤2.1 h occasional smokers' after smoking. Cannabigerol (CBG), Δ9-tetrahydrocannabivarin (THCV), 11-nor-9-carboxy-THCV might also markers, but their pharmacokinetics have not been investigated. Additionally, while smoking the most common...

10.1373/clinchem.2016.263475 article EN Clinical Chemistry 2016-10-11

Objectives: Cannabidiol (CBD) is hypothesized as a potential treatment for opioid addiction, with safety studies an important first step medication development. We determined CBD and pharmacokinetics when administered concomitantly high-potency in healthy subjects. Methods: This double-blind, placebo-controlled cross-over study of CBD, coadministered intravenous fentanyl, was conducted at the Clinical Research Center Mount Sinai Hospital, tertiary care medical center New York City....

10.1097/adm.0000000000000118 article EN Journal of Addiction Medicine 2015-03-06

The current lack of pharmacological treatments for cannabis use disorder (CUD) warrants novel approaches and further investigation promising pharmacotherapy. We previously showed that nabiximols (27 mg/ml Δ9-tetrahydrocannabinol (THC)/ 25 cannabidiol (CBD), Sativex®) can decrease withdrawal symptoms. Here, we assessed in a pilot study the tolerability safety self-titrated vs. placebo among 40 treatment-seeking cannabis-dependent participants.Subjects participated double blind randomized...

10.1371/journal.pone.0190768 article EN public-domain PLoS ONE 2018-01-31

Oral fluid (OF) is an accepted alternative biological matrix for drug treatment, workplace, and DUID (driving under the influence of drugs) investigations, but establishing cannabinoid OF detection window concentration cutoff criteria are important.Cannabinoid concentrations were quantified in from chronic, daily cannabis smokers during monitored abstinence. Δ(9)-tetrahydrocannabinol (THC)(3), cannabidiol (CBD), cannabinol (CBN), 11-nor-9-carboxy-THC (THCCOOH) determined samples collected...

10.1373/clinchem.2011.164822 article EN Clinical Chemistry 2011-06-15

Cocaine is rapidly metabolized to major metabolites, benzoylecgonine (BE) and ecgonine methyl ester (EME), minor norcocaine, p-hydroxycocaine, m-hydroxycocaine, p-hydroxybenzoylecgonine (pOHBE), m-hydroxybenzoylecgonine. This IRB-approved study examined cocaine metabolite plasma concentrations in 18 healthy humans who provided written informed consent receive low (75 mg/70 kg) high (150 subcutaneous hydrochloride doses. Plasma specimens, collected prior up 48 h after dosing, were analyzed by...

10.1093/jat/30.8.501 article EN Journal of Analytical Toxicology 2006-10-01

The ease, noninvasiveness, and safety of oral fluid collection have increased the use this alternative matrix for drugs-of-abuse testing; however, few controlled drug administration data are available to aid in interpretation results.Single codeine doses (60 120 mg/70 kg) were administered 19 volunteers. Oral plasma analyzed free codeine, norcodeine, morphine, normorphine by solid-phase extraction combined with gas chromatography-mass spectrometry (SPE/GC-MS). Physiologic subjective effects...

10.1093/clinchem/48.9.1486 article EN Clinical Chemistry 2002-09-01

Oral fluid is an attractive alternative matrix for drug testing with a noninvasive and directly observed collection, but there are few controlled cocaine administration studies to guide interpretation.

10.1097/ftd.0b013e3181f2b729 article EN Therapeutic Drug Monitoring 2010-09-02

Abstract BACKGROUND We measured Δ9-tetrahydrocannabinol (THC), 11-nor-9-carboxy-THC (THCCOOH), cannabidiol (CBD), and cannabinol (CBN) disposition in oral fluid (OF) following controlled cannabis smoking to evaluate whether monitoring multiple cannabinoids OF improved test interpretation. METHODS Cannabis smokers provided written informed consent for this institutional review board–approved study. was collected with the Quantisal™ device ad libitum of one 6.8% THC cigarette. Cannabinoids...

10.1373/clinchem.2011.177881 article EN Clinical Chemistry 2012-01-24

Defining cannabinoid stability in authentic oral fluid (OF) is critically important for result interpretation. There are few published OF data, and of those available, all employed fortified synthetic solutions or elution buffers; none included following controlled cannabis smoking.

10.1373/clinchem.2012.184929 article EN Clinical Chemistry 2012-04-25

Knowing the time cannabis was last used is important for determining impairment in accident investigations and clinical evaluations. Two models predicting of use from single plasma cannabinoid concentrations-model I, using Delta(9)-tetrahydrocannabinol (THC), model II, concentration ratio 11-nor-9-carboxy-THC (THCCOOH) to THC-were developed validated controlled drug administration studies. Objectives current study were extend validation by a large number samples collected after multiple...

10.1373/clinchem.2005.056838 article EN Clinical Chemistry 2005-10-14

Sweat testing is a noninvasive technique for monitoring drug exposure in treatment, criminal justice, and employment settings.We evaluated cocaine excretion 9 participants' sweat after they received 3 low doses (75 mg/70 kg) of HCl subcutaneously within 1 week and, weeks later, high (150 kg). Six additional participants completed portions the study. PharmChek patches (n = 1390) were collected throughout 3-week washout period, reflecting previously self-administered drugs, during controlled...

10.1373/clinchem.2005.054338 article EN Clinical Chemistry 2005-09-16

A previously recommended a method for detecting new cannabis use with creatinine-normalized 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) urine concentrations in periodically collected specimens treatment, workplace and judicial drug testing applications is refined by considering the time interval between collections. All were from six less-than-daily users who smoked placebo, 1.75%, 3.55% THC cigarettes randomized order, each separated one week. Ratios (n = 24,322) calculated dividing...

10.1093/jat/33.4.185 article EN Journal of Analytical Toxicology 2009-05-01

Oral fluid (OF) testing offers noninvasive sample collection for on-site drug testing; however, to date, test performance Δ(9)-tetrahydrocannabinol (THC) detection has had unacceptable diagnostic sensitivity. On-site tests must accurately identify cannabis exposure because this accounts the highest prevalence in workplace and driving under influence of drugs (DUID) programs.

10.1373/clinchem.2012.189001 article EN Clinical Chemistry 2012-08-23

A randomized, placebo-controlled crossover trial utilizing vaporized cannabis containing placebo and 6.7% 2.9% delta-9-tetrahydrocannabinol (THC) was performed in 42 subjects with central neuropathic pain related to spinal cord injury disease. Subjects received two administrations of the study medication a 4-hour interval. Blood samples for pharmacokinetic evaluation were collected, assessment tests immediately after second administration 3 hours later. Pharmacokinetic data, although...

10.2147/jpr.s113138 article EN cc-by-nc Journal of Pain Research 2016-08-01

Oral fluid (OF) is an increasingly popular alternative matrix for drug testing, with cannabinoids being the most commonly identified illicit drug. Quantification of multiple OF and understanding differences in cannabinoid pharmacokinetics between frequent occasional smokers improve test interpretation. The new Oral‐Eze® collection device has elution buffer that stabilizes analytes improves recovery from pad; however, its performance not been independently evaluated. After controlled smoking...

10.1002/dta.1632 article EN Drug Testing and Analysis 2014-03-20
Coming Soon ...